cbc.caNov 6$MRNA

Moderna's mRNA flu and flu-COVID combo vaccines have been approved by Health Canada

Health Canada approved Moderna's mRNA flu vaccine (mFLUSIVA) and a combo flu-COVID-19 vaccine (mCOFLU) for adults 50+. Moderna stated the vaccines won't be available this season. The National Advisory Committee on Immunization recommends non-mRNA flu shots for all ages six months and older, and COVID-19 vaccines for those 65+ and long-term care residents. Moderna's vaccines were previously approved in the U.S. and Europe.

Original reporting

cbc.ca

Published Nov 6, 2026, 4:39 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 6, 2026, 6:29 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Moderna's mRNA flu and flu-COVID combo vaccines have been approved by Health Canada — source image — Source · cbc.ca

Decision brief

The 30-second read

$MRNABullishMed

Why it matters

The approval expands Moderna's product pipeline and could generate multi‑year revenue, though immediate sales are limited by distribution timing.

Market read

Regulatory clearance in a new market is a material catalyst for Moderna, likely prompting a short‑term price uptick and longer‑term revenue upside.

What to watch

Potential competition from other flu vaccines and the need for supply chain readiness in Canada.

Relevance 7/10Novelty 8/10Timing: immediate, same‑day reaction

Background

Moderna announced that Health Canada authorized its mRNA flu vaccine (mFLUSIVA) and flu‑COVID combo (mCOFLU) for adults 50+, but noted the products will not reach pharmacies in time for the current flu season.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MRNABullishHigh confidence

Context

Health Canada approved Moderna's mRNA flu vaccine and its flu‑COVID combo, a first for the company in Canada.

Expected impact

likely upward pressure as investors price in additional revenue potential

Evidence & confidence

Regulatory clearance is a primary catalyst; the market has not priced this Canadian approval yet.

Market effects

Sector

Strengthens the biotech/healthcare sector's outlook on mRNA platforms and may boost related vaccine developers.

Regional

Positive for Canadian biotech and pharmaceutical stocks as a new product enters the market.

Global

Adds to global confidence in mRNA technology, potentially influencing other markets.

Counterpoint

What could challenge this read

If the vaccine faces distribution delays, the short‑term stock boost could be muted.

Key entities

Company
Moderna Inc.
Developer of the approved mRNA flu and flu‑COVID vaccines.
Regulator
Health Canada
Canadian health authority that granted the approvals.

Read at source ← All news

$MRNAHighAI 9/10

Moderna lifts annual revenue forecast | The Manila Times

Moderna raised its annual revenue forecast due to strong international Covid-19 vaccine demand and partnership payments, reporting a profit in Q3. Its shares rose over 10 percent.

linkedin.comNov 7

$MRNAMedAI 8/10

Moderna lifts annual revenue forecast

Moderna raised its 2026 revenue forecast to 15-25% growth, up from 10%, due to strong vaccine demand and partnerships. Q3 revenue was $1.3B, beating estimates. The company reported a $162M profit, reversing last year's $200M loss. Shares rose over 10% after the announcement, driven by positive cancer vaccine data and future growth prospects.

manilatimes.netNov 7

$MRNAHighAI 8/10

What Is Behind The Rise In Moderna Stock?

Moderna (MRNA) shares rose 5.3% on November 6, 2026, after reporting Q3 revenue of $1.3B, beating estimates, and raising its 2026 revenue growth outlook to 15-25%. The company also reduced its R&D budget by $200M. The stock has gained 978.9% over the past year, with significant volatility.

finance.yahoo.comNov 7

$GSKLow

GSK, Moderna settle patent fight over COVID-19 and RSV vaccines without payments

GSK and Moderna settled their patent dispute over COVID-19 and RSV vaccine technology without payments. The agreement allows both to use each other's patented technologies. GSK sued Moderna in 2024, alleging patent infringement. The settlement covers Moderna's Spikevax, mNEXSPIKE, and mResvia vaccines. Both companies requested dismissal of GSK's US claims. This resolves one of several legal battles among pharmaceutical companies over COVID-19 vaccine technology.

bilyonaryo.comNov 7

$MRNAHigh

Health Canada approves Moderna's new mRNA shots for flu, flu-COVID combo

Health Canada approved two Moderna mRNA vaccines: one for flu and another for flu and COVID-19. Approval is for individuals aged 50 and older. Moderna develops vaccines.

cbc.caNov 7